Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding
暂无分享,去创建一个
D. Loebenberg | R. Palermo | V. Madison | Robert E. Palermo | Li Xiao | A. Chau | P. McNicholas | David Loebenberg | Vincent Madison | Li Xiao | Andrew S. Chau | Paul M. McNicholas
[1] R Sánchez,et al. Advances in comparative protein-structure modelling. , 1997, Current opinion in structural biology.
[2] J. Peterson,et al. How similar are P450s and what can their differences teach us? , 1999, Archives of biochemistry and biophysics.
[3] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[4] D. Sheehan,et al. Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.
[5] Cytochrome P450. , 1995, Current opinion in structural biology.
[6] D. Sanglard,et al. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.
[7] M. Pfaller,et al. In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. andCryptococcus neoformans , 2001, Antimicrobial Agents and Chemotherapy.
[8] D. Loebenberg,et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. , 2003, The Journal of antimicrobial chemotherapy.
[9] A. Sali,et al. Large-scale protein structure modeling of the Saccharomyces cerevisiae genome. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[10] E. Mellado,et al. A Point Mutation in the 14α-Sterol Demethylase Gene cyp51A Contributes to Itraconazole Resistance in Aspergillus fumigatus , 2003, Antimicrobial Agents and Chemotherapy.
[11] M H Tarbit,et al. Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. , 1999, Journal of enzyme inhibition.
[12] T. Poulos,et al. Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[13] D. Loebenberg,et al. Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-Demethylase , 2003, Antimicrobial Agents and Chemotherapy.
[14] M. D. de Groot,et al. Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei , 2003, Antimicrobial Agents and Chemotherapy.
[15] D E McRee,et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.
[16] C. Fattorusso,et al. Construction of a model of the Candida albicans lanosterol 14-alpha-demethylase active site using the homology modelling technique. , 1998, Pharmaceutica acta Helvetiae.
[17] Andrej ⩽ali,et al. Comparative protein modeling by satisfaction of spatial restraints , 1995 .
[18] G. Costantino,et al. 1,4-Benzothiazine and 1,4-benzoxazine imidazole derivatives with antifungal activity: a docking study. , 2002, Bioorganic & medicinal chemistry.
[19] D. Loebenberg,et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). , 2000, The Journal of antimicrobial chemotherapy.
[20] P. Marichal,et al. Anti-Candida drugs--the biochemical basis for their activity. , 1987, Critical reviews in microbiology.
[21] Wannian Zhang,et al. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. , 2000, Journal of medicinal chemistry.
[22] T. Poulos,et al. The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid , 1997, Nature Structural Biology.
[23] T. Poulos,et al. Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. , 2001, Journal of inorganic biochemistry.
[24] E. Mellado,et al. Identification of Two Different 14-α Sterol Demethylase-Related Genes (cyp51A and cyp51B) in Aspergillus fumigatus and Other Aspergillus species , 2001, Journal of Clinical Microbiology.
[25] Guy H. Grant,et al. Modeling cytochrome P450 14α demethylase (Candida albicans) from P450cam , 1994 .
[26] C David Stout,et al. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. , 2003, Biochemistry.
[27] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[28] G. Goldman,et al. Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole , 2003, Antimicrobial Agents and Chemotherapy.
[29] J. Peterson,et al. A close family resemblance: the importance of structure in understanding cytochromes P450. , 1998, Structure.
[30] N. Shimma,et al. Modeling, synthesis and biological activity of novel antifungal agents (1). , 1998, Bioorganic & medicinal chemistry letters.